New obesity drug UBT251 enters Mid-Stage trial
NCT ID NCT07395687
First seen Feb 14, 2026 · Last updated Apr 24, 2026 · Updated 5 times
Summary
This study tests whether UBT251 is safe and helps people with overweight or obesity lose weight. About 333 adults will receive either the drug or a placebo. The main goal is to measure side effects and weight change over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Company, Inc
RECRUITINGMontreal, Quebec, H3P 3P1, Canada
-
Altasciences Clinical Kansas, Inc.
RECRUITINGOverland Park, Kansas, 66212, United States
-
Altasciences Clinical LA, Inc.
RECRUITINGCypress, California, 90630, United States
Conditions
Explore the condition pages connected to this study.